-
Autumn update: Report progress and exciting things to come
As we come out of a summer of great progress we have been looking back on where we have come in the last year. We have made great strides in the last few months standing up our website, delivering our first set of reports and making big developments to the BioFast. We have welcome Conor […]
-
Insight: What Karyopharm’s new trial data means for cancer drug development
*** This is a sample article, the information provided is an example *** The latest trial from Karyopharm has just released its new results. The selenexor compound has shown good results in the stage 3 trials. Whilst this was an expected result to the biotech world and individually has little impact it lays the path […]
-
Cambridge Bio Nexus: A new player in the world of BioTech investing
Cambridge Bio Nexus: A new player in the world of BioTech investing offers a fresh new perspective in the world of investing for biotech. Gone are the days when investors are left scraping their heads if a new wonder drug will really be what its promised to be. BioFast allowed me to get clued into […]
